Off-Label Drugs. Initial Results of a National Survey

Abstract

The U.S. Senate Committee on Labor and Human Resources has asked the General Accounting Office (GAO) to conduct a study of the extent to which there are reimbursement denials when anticancer drugs are used for clinical indications other than that for which they received approval from the Food and Drug Administration. GAO is primarily interested in reimbursement problems as they relate to off-label anticancer drug use and the potential effects these problems might have on the therapies given to cancer patients. This questionnaire is part of a national survey of oncologists and hematologists in private practice.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Feb 01, 1991
Accession Number
ADA270395

Entities

Organizations

  • United States Government Accountability Office

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biological Therapy
  • Breast Cancer
  • Cancer
  • Chemistry
  • Colon Cancer
  • Diseases And Disorders
  • Drug Combinations
  • Health
  • Health Care
  • Health Services
  • Hodgkins Disease
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Pharmaceutical Preparations
  • Physicians
  • Therapy

Fields of Study

  • Political science

Readers

  • Government Contracting/Procurement.
  • Oncology